Shabbir Safdar
Hematology & Oncology · Saint Louis, MONPI 1952380107
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 62.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $6,071 and has fallen 99.6% since, to $24 in 2023.
Across 178 payments — averaging $36.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- Novartis$262
- Merck$218
- E.r. Squibb & Sons, L.L.C.$207
- Johnson & Johnson$198
- Bristol Myers Squibb$174
- plus $1K from 25 others
What the payments were for
- Consulting fees$3,30051%
- Speaking & faculty fees$250%
- Travel & lodging$4887%
- Food & beverage$2,39537%
- Education$3165%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $4,063 |
| Novartis | 16 | $262 |
| Merck | 14 | $218 |
| E.r. Squibb & Sons, L.L.C. | 16 | $207 |
| Johnson & Johnson(2 entities) | 10 | $198 |
| Bristol Myers Squibb | 17 | $174 |
| Sanofi | 10 | $174 |
| Genentech USA, Inc. | 13 | $156 |
| AstraZeneca(2 entities) | 8 | $156 |
| Amgen | 8 | $129 |
| Pfizer | 14 | $125 |
| Secura Bio, Inc. | 2 | $59 |
| Lilly USA, LLC | 4 | $57 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Kyowa Kirin, Inc. | 3 | $51 |
| Eisai Inc. | 3 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Gilead | 3 | $36 |
| Bayer | 2 | $36 |
| Foundation Medicine, Inc. | 2 | $34 |
| Tersera Therapeutics LLC | 2 | $34 |
| Seagen Inc. | 2 | $30 |
| Tesaro, Inc. | 1 | $28 |
| Abbott | 1 | $21 |
| AbbVie | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Verastem, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$6,525 in reported general payments places this provider in the 75th percentile of 211 hematology & oncology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 26 | $593 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Saint Louis
- Mark FeslerSaint Louis$870K
- Jonathan MizrahiSaint Louis$188K
- Geoffrey UySaint Louis$28K
- Deepthi BusayavalasaSaint Louis$22K
- Jason LiSaint Louis$17K
- John FinnieSaint Louis$14K
- Atif ShafqatSaint Louis$7K
- Bryan FallerSaint Louis$6K
- Heide RodgersSaint Louis$6K
- Mhd RajehSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.